This month, the annual cancer research summit, #AACR, arrived in San Diego, USA! Focused on #tumor research and innovation, top global achievements were fully showcased. Under China’s Biopharmaceuticals, the new drug, Anlotinib from Zhongda Tianqing, shines brightly!

Latest Research Progress

ALTER-G-001, a diversified and cross-regional Phase II study, unveiled the latest results of Cohort C. Patients receiving Anlotinib + standard chemotherapy for 6 cycles showed remarkable efficacy. Anlotinib combined with chemotherapy, especially demonstrated significant effects in pancreatic cancer patients!

Key Data

Enrolled 41 patients, covering various cancer types including pancreatic, #gastric, #biliarytract, and #duodenal cancer,

ORR reached 42.3% in #pancreaticcancer patients

DCR soared to 88.5%

Median PFS reached 5.8 months

After efficacy assessment, tumors in 14 SD patients showed shrinkage

Treatment Outlook

Research results indicate that Anlotinib combined with chemotherapy as first-line treatment, particularly for digestive tract tumors with unresectable liver metastases, especially in pancreatic cancer patients, has significant efficacy. This may open up a completely new treatment path for such patients, bringing new hope!

Embark on an exploration of life from here!

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com